- Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
The Free Markets ETF(FMKT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for FMKT
11/20/2026: FMKT (1-star) is currently NOT-A-BUY. Pass it for now.
The Free Markets ETF (FMKT) is an actively managed fund providing targeted exposure to U.S. companies positioned to benefit from deregulation across sectors like energy, healthcare, and finance. Its main strengths lie in its pioneering thematic focus and active management flexibility. It serves well as a satellite holding for tactical growth investors looking to capture policy-driven tailwinds. Key risks include a concentrated portfolio, a relatively high expense ratio of 0.76%, and a short operating history with lower liquidity. Investors should monitor regulatory developments and trading spreads when evaluating positions.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Suits growth investors looking for corporate acceleration driven by administrative relief. |
| Momentum investor | Strong fit while signal remains positive | Appeals to momentum strategies when regulatory-themed sectors outperform. |
| Value investor | Mixed fit | Offers exposure to cash-flow heavy sectors like energy and finance, though valuation varies. |
| Dividend/Income investor | Mixed fit | Provides modest dividend yields from underlying blue-chip holdings, but income is not the core mandate. |
| Low-risk investor | Weak fit | The concentrated nature and active strategy introduce higher idiosyncratic equity volatility. |
Investor Profile
Ideal Investor Profile
Tactical growth investors seeking targeted exposure to policy-driven macroeconomic shifts and regulatory relief.
Suitability
Best utilized as a satellite holding within a broader core portfolio rather than a primary long-term anchor.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | Medium / high | Concentrated stock holdings can experience sharp price swings. |
| Market risk | High | Overall equity market downturns will negatively affect portfolio value. |
| Concentration | High | Holding a limited number of positions increases single-stock impact. |
| Tracking/expense | Medium | An expense ratio of 0.76% creates a higher hurdle than passive index funds. |
| Liquidity | Medium / high | Lower AUM can result in wider bid-ask spreads during market stress. |
| Business/sector quality | Medium | Success relies heavily on the actual realization of regulatory benefits. |
Sector & Industry Intelligence
This fund is not assigned to one sector.
Risk Analysis
Volatility
FMKT exhibits elevated historical volatility due to its concentrated basket of sector-specific equities.
Market Risk
Primary risks stem from systematic market pullbacks and the success or failure of corporate deregulation efforts.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Single stock | Welltower Inc. (WELL) | 5.46 | Provides top-tier healthcare real estate exposure positioned to gain from easing institutional constraints. |
| Single stock | Chevron Corp. (CVX) | 5.03 | Offers major energy exposure leveraged to potential leasing and environmental permitting reforms. |
| Single stock | ConocoPhillips (COP) | 5 | Delivers upstream oil and gas exposure benefiting from streamlined operational approvals. |
| Single stock | Regeneron Pharmaceuticals (REGN) | 4.9 | Gives biotechnology exposure sensitive to drug approval processes and regulatory frameworks. |
| Single stock | Biogen Inc. (BIIB) | 4.58 | Provides specialized neurological therapeutic exposure impacted by healthcare policy shifts. |
| Other | Remaining Portfolio Holdings (Eli Lilly, Interactive Brokers, Robinhood, Deere, CoreSite, etc.) | 75.03 | Comprises the rest of the actively managed basket across technology, finance, and industrial sectors. |
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type ETF | Historic Profit -8.19% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | ETF Returns Performance |

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

